Peter Ngo
Laredo, TXNPI 1417918525
Payments from drug & device makers
Across 251 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$650
- Merck$598
- Novo Nordisk$577
- Lilly USA, LLC$495
- AbbVie$267
- Abbott$197
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,17999%
- Education$461%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 36 | $650 |
| Merck | 46 | $598 |
| Novo Nordisk | 43 | $577 |
| Lilly USA, LLC | 27 | $495 |
| AbbVie | 12 | $267 |
| Abbott | 12 | $197 |
| Amgen | 11 | $196 |
| AstraZeneca(2 entities) | 10 | $178 |
| Xeris Pharmaceuticals, Inc. | 7 | $138 |
| Medtronic(2 entities) | 4 | $130 |
| Esperion Therapeutics, Inc. | 7 | $127 |
| Amryt Pharma Holdings Ltd | 5 | $100 |
| Sanofi-aventis U.S. LLC | 5 | $100 |
| Dexcom, Inc. | 4 | $85 |
| Corcept Therapeutics | 4 | $83 |
| Ultragenyx Pharmaceutical Inc. | 2 | $42 |
| IBSA Pharma Inc. | 3 | $42 |
| Bayer | 2 | $32 |
| Recordati_rare_diseases_inc. | 1 | $29 |
| Ascensia Diabetes Care US Inc. | 2 | $28 |
| Bigfoot Biomedical Inc | 1 | $22 |
| Evoke Pharma, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Tandem Diabetes Care, Inc. | 1 | $12 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $33,122 |
| TrulicityDulaglutide | 14 | $16,968 |
| MounjaroTirzepatide | 11 | $13,772 |
| FarxigaDapagliflozin Propanediol | 13 | $10,785 |
| SynthroidLevothyroxine Sodium | 16 | $1,598 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,053 |
| Rosuvastatin Calcium | 49 | $708 |
| Levothyroxine Sodium | 39 | $459 |
| Atorvastatin Calcium | 48 | $453 |
| Gabapentin | 14 | $287 |
| Ezetimibe | 18 | $231 |
| Losartan Potassium | 12 | $141 |
| Glimepiride | 17 | $112 |
| Alendronate Sodium | 11 | $95 |
| Lisinopril | 14 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $577 | $33,12220 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $495 | $30,74025 claims |
| AstraZenecaFarxiga | $178 | $10,78513 claims |
| AbbVieSynthroid | $267 | $1,59816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Texason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.